Brief: FDA Accepts For Review BLA For Dmb-3115 Of Dong-A St, A Proposed Biosimilar To Stelara®
05/01/2024 14:33
Jan 5 (Reuters) - Dong-A ST Co Ltd 170900.KS :
* FDA ACCEPTS FOR REVIEW BLA FOR DMB-3115 OF DONG-A ST, A
PROPOSED
BIOSIMILAR TO STELARA® (USTEKINUMAB)
* ACCORD BIOPHARMA, UNIT OF INTAS PHARMACEUTICALS GOT
NOTIFICATION
THAT FDA ACCEPTED ITS BIOLOGICS LICENSE APPLICATION FOR DMB-3115
Source text for Eikon: ID:nBw75hTBda
Further company coverage: 170900.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dong-A ST
See all newsBrief: Dong-A St Q1 Operating Profit 10.8 Billion Won, Up 53.7% From Year Earlier
Brief: Dong-A St To Cancel 5 Billion Won Worth Of Own Shares
Brief: Dong-A St Q4 Operating Loss 554 Million Won
Brief: Dong-A St Q2 Operating Profit 4 Billion Won, Down 43.4% From Year Earlier
Brief: Dong-A St Q1 Operating Profit 7 Billion Won, Up 854% From Year Earlier